In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk
PMID: 37665995
Source: Ann Intern Med
Publication date:
2025-07-24
Year:
2023
Abstract
Loftus EV Jr, Panes J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023;388:1966-1980. 37224198.